3D Medicines (HKG:1244) has filed for patent under the Patent Cooperation Treaty for a key component of its ionizable cationic lipid in the lipid nanoparticles for nucleic acid drug delivery, a Tuesday filing with the Hong Kong bourse said.
The biopharmaceutical company has created an ionizable cationic lipid R&D platform targeting different cell types and organs by using AI to design and screen hundreds of lipid compounds.
The platform synergizes with the development of the firm's self-developed mRNA cancer vaccine projects, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。